ArticlePeerJ2026
Analysis of biochemical parameters and tumor markers in Cushing's disease and ectopic adrenocorticotropic hormone syndrome.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare clinical characteristics, biochemical parameters, and tumor markers between patients with Cushing disease (CD) and ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS), identify potential biomarkers, and optimize their diagnostic differentiation. Methods: A single-center retrospective study was conducted in 75 patients with ACTH-dependent Cushing syndrome (51 CD, 24 EAS) admitted between January 2006 and April 2025. Differences in biochemical indices, tumor markers, and hormone levels were analyzed. Receiver operating characteristic (ROC) analysis was used to evaluate diagnostic performance and determine optimal cut-off values. Results: EAS patients were significantly older at diagnosis than CD patients. Fasting glucose was higher, while serum potassium and albumin were lower in the EAS group. Non-small cell lung cancer-associated antigen, carcinoembryonic antigen (CEA), cancer antigen 15-3 (CA15-3), and cancer antigen 19-9 were markedly elevated in EAS, whereas pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) showed no significant differences. Serum cortisol and plasma ACTH levels at all time points and after dexamethasone suppression were significantly higher in EAS. ROC analysis of the product of midnight serum cortisol (μg/dL) and plasma ACTH (pg/mL) divided by 1000 ("Midnight Cort × ACTH/1000") showed an area under the curve (AUC) of 0.902 for identifying EAS, with a cut-off value >2 (sensitivity 83.3%, specificity 84.3%). Its diagnostic accuracy was comparable to that of the high-dose dexamethasone suppression test (HDDST). Conclusion: EAS patients were older and exhibited more severe metabolic abnormalities than those with CD. Elevated tumor markers may suggest ectopic ACTH secretion. The "Midnight Cort × ACTH/1000" index provides high diagnostic value and a simple, convenient method for differentiating EAS from CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.